including the biorepository. The National Defense Authorization Act of 2008 (PL 110-181, § 722) later created the Joint Pathology Center (JPC) to absorb the AFIP biorepository and continue its duties.

As the transition to the JPC was taking place in 2010, the Department of Defense (DoD) asked the Institute of Medicine (IOM) to convene an expert committee to offer advice on several issues related to the operation of the biorepository and the management of its collection. The questions posed in its statement of task (Box S-1) were focused on issues related to the appropriate future use of the specimens in consultation, education, and research. This report, prepared by the IOM Committee on the Review of

Questions Posed in the Committee’s Statement of Task

  • Given the defined mission and vision of the Joint Pathology Center, should access to repository materials be limited to the federal government or open to a larger pool of potential users? What advantages and disadvantages should be considered in defining the potential users of the repository in research?
  • What are the ethical and legal considerations regarding utilization of the tissue repository in support of clinical care and education?
  • The tissue repository currently contains paraffin embedded tissue, glass slides, wet (formalin-fixed tissue) and frozen tissue; some of it is not usable for consultation, education, and research given current technology. Should material not deemed currently usable for consultation, education, and research be stored indefinitely or should the JPC develop a plan for disposal of unusable or nonviable specimens and are there any legal considerations with disposal of said specimens?
  • Should the BRAC Collection of materials be maintained indefinitely?
  • Can tissue collected for clinical use be used for research (i.e., from patients not specifically consented for use of tissue in research)?
  • What are the ethical considerations regarding use of tissues originally submitted for clinical use for research and can this be accomplished within current accepted guidelines for clinical research?
  • The tissue repository currently contains consult material from both federal facilities as well as that submitted for consultation by civilian providers. Can tissue within the repository from civilian providers be utilized in the same manner as that from federal facilities?
  • What considerations should be given to utilization for research of unique, one-of-a-kind material within the Central Collection of the tissue repository?
  • What existing or emerging technologies (either as an intrinsic function or through partnership) should be considered in developing a plan for utilization of the tissue repository in research and how would they potentially affect the mission of the JPC?

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement